FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA

被引：0

作者：

Lazaridis, L. ^{[1
,2
]}

Schmidt, T. ^{[1
,2
]}

Agkatsev, S. ^{[1
,2
]}

Blau, T. ^{[3
]}

Spille, D. ^{[4
]}

Heider, S. ^{[5
]}

Schulz, T. ^{[6
]}

Bumes, E. ^{[7
]}

Oster, C. ^{[1
,2
]}

Feldheim, J. ^{[1
,2
]}

Stummer, W.

Kessler, A. ^{[6
]}

Seidel, C. ^{[5
]}

Hau, P. ^{[7
]}

Sure, U. ^{[8
]}

Keyvani, K. ^{[3
]}

Herrlinger, U. ^{[9
]}

Kleinschnitz, C. ^{[1
,2
]}

Stuschke, M. ^{[10
]}

Herrmann, K. ^{[11
]}

Deuschl, C. ^{[12
]}

Hattingen, E. ^{[13
]}

Scheffler, B. ^{[14
]}

Kebir, S. ^{[1
,2
]}

Glas, M. ^{[1
,2
]}

机构：

[1] Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TN, Essen, Germany

[2] Univ Med Essen, Dept Neurol, Essen, Germany

[3] Univ Med Essen, Inst Neuropathol, Essen, Germany

[4] Univ Hosp Munster, Dept Neurosurg, Munster, Germany

[5] Univ Hosp Leipzig, Dept Radiotherapy & Radiat Oncol, Leipzig, Germany

[6] Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany

[7] Univ Hosp Regensburg, Dept Neurol & Wilhelm Sander NeuroOncol Unit, Regensburg, Germany

[8] Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[9] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol & Ctr Integrated Oncol, Bonn, Germany

[10] Univ Med Essen, Dept Radiotherapy, Essen, Germany

[11] Univ Med Essen, Dept Nucl Med, Essen, Germany

[12] Univ Med Essen, Inst Diagnost & Intervent Radiol & Neurora, Essen, Germany

[13] Univ Hosp Frankfurt, Inst Neuroradiol, Frankfurt, Germany

[14] Univ Med Essen, West German Canc Ctr WTZ, DKFZ Div Translat Neurooncol, DKTK Partner Site, Essen, Germany

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

10.1093/neuonc/noac174.204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P11.15.B

引用

页数：2

共 50 条

[21] Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
Lazaridis, Lazaros
Schaefer, Niklas
Teuber-Hanselmann, Sarah
Blau, Tobias
Schmidt, Teresa
Oster, Christoph
Weller, Johannes
Tzaridis, Theophilos
Pierscianek, Daniela
Keyvani, Kathy
Kleinschnitz, Christoph
Stuschke, Martin
Scheffler, Bjoern
Deuschl, Cornelius
Sure, Ulrich
Herrlinger, Ulrich
Kebir, Sied
Glas, Martin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 787 - 792
[22] Benefits of Interferon-β and Temozolomide Combination Therapy for Newly Diagnosed Primary Glioblastoma With the Unmethylated MGMT Promoter A Multicenter Study
Motomura, Kazuya
Natsume, Atsushi
Kishida, Yugo
Higashi, Hiroyuki
Kondo, Yutaka
Nakasu, Yoko
Abe, Tatsuya
Namba, Hiroki
Wakai, Kenji
Wakabayashi, Toshihiko
CANCER, 2011, 117 (08) : 1721 - 1730
[23] PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA
Pan, Peter
Haggiagi, Aya
Iwamoto, Fabio
NEURO-ONCOLOGY, 2022, 24 : 6 - 6
[24] Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma
Funakoshi, Yusuke
Hata, Nobuhiro
Takigawa, Kosuke
Arita, Hideyuki
Kuga, Daisuke
Hatae, Ryusuke
Sangatsuda, Yuhei
Fujioka, Yutaka
Sako, Aki
Umehara, Toru
Yoshitake, Tadamasa
Togao, Osamu
Hiwatashi, Akio
Yoshimoto, Koji
Iwaki, Toru
Mizoguchi, Masahiro
CANCER MEDICINE, 2021, 10 (10): : 3177 - 3187
[25] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
Lombardi, Giuseppe
Giunco, Silvia
Cavallin, Francesco
Angelini, Chiara
Caccese, Mario
Cerretti, Giulia
De Bonis, Pasquale
De Rossi, Anita
Zagonel, Vittorina
NEURO-ONCOLOGY, 2021, 23 : 15 - 15
[26] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15)
Padovan, M.
De Salvo, G.
Cerretti, G.
Krengli, M.
Caccese, M.
Maccari, M.
Farina, M.
Bergo, E.
Zabeo, C.
Grosso, D.
Caumo, F.
Coppola, M.
D'Avolio, A.
Zagonel, V.
Lombardi, G.
NEURO-ONCOLOGY, 2023, 25
[27] A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
Weller, Michael
Lim, Michael
Idbaih, Ahmed
Steinbach, Joachim
Finocchiaro, Gaetano
Raval, Raju
Ashby, Lynn
Ansstas, George
Baehring, Joachim
Taylor, Jennie
Honnorat, Jerome
Petrecca, Kevin
De Vos, Filip
Wick, Antje
Sumrall, Ashley
Roberts, Mustimbo
Slepetis, Ruta
Warad, Deepti
Lee, Michelle
Reardon, David
Omuro, Antonio
NEURO-ONCOLOGY, 2021, 23 : 55 - 56
[28] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Lazaridis, Lazaros
Schaefer, Niklas
Kebir, Sied
Weller, Johannes
Tzaridis, Theophilos-Dimitrios
Scheffler, Bjoern
Pierscianek, Daniela
Kleinschnitz, Christoph
Stuschke, Martin
Sure, Ulrich
Herrlinger, Ulrich
Glas, Martin
NEURO-ONCOLOGY, 2018, 20 : 119 - 120
[29] Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
Lazaridis, L.
Kebir, S.
Weller, J.
Tzaridis, T. -D
Scheffler, B.
Pierscianek, D.
Kleinschnitz, C.
Stuschke, M.
Sure, U.
Herrlinger, U.
Schaefer, N.
Glas, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S109 - S109
[30] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Lazaridis, L.
Schaefer, N.
Kebir, S.
Weller, J.
Tzaridis, T.
Schaeffler, B.
Pierscianek, D.
Kleinschnitz, C.
Stuschke, M.
Sure, U.
Herrlinger, U.
Glas, M.
NEURO-ONCOLOGY, 2018, 20 : 230 - 230

← 1 2 3 4 5 →